Multicenter, randomized, double-blind, placebo controlled, crossover single dose study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, effect on gastric emptying of TZP-101 IV infusion in diabetic gastroparesis patients

Trial Profile

Multicenter, randomized, double-blind, placebo controlled, crossover single dose study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, effect on gastric emptying of TZP-101 IV infusion in diabetic gastroparesis patients

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2009

At a glance

  • Drugs Ulimorelin (Primary) ; Ghrelin agonists
  • Indications Diabetic gastroparesis; Gastroparesis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 04 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top